Bicycle Therapeutics welcomes Dr. Jose-Carlos Gutierrez-Ramos to its Board of Directors

– UK, Cambridge –  Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, today announced the appointment of Dr. Jose-Carlos Gutierrez-Ramos, Ph.D., to its Board of Directors.

Dr. Gutierrez-Ramos previously served as the Chair of Bicycle’s Scientific Advisory Board and has extensive experience in leading biopharmaceutical companies and scientific groups in the world’s top academic institutions.

“We are delighted to welcome JC back to the Bicycle team as a Board member. JC has dedicated his entire career, most of it in senior leadership roles in pharma, to evolving emerging science and new technologies into novel and important therapeutics. His deep experience and future contributions will be invaluable to the Board and the ongoing success of the company,” said CEO, Dr. Kevin Lee.

He added: “We look forward to benefitting from JC’s substantial expertise as a preeminent drug development leader as we continue to advance our broad clinical oncology pipeline and in parallel extend the novel Bicycle platform to address multiple unmet medical needs in other significant diseases.”

About Dr. Gutierrez-Ramos

Dr. Gutierrez-Ramos serves as Chief Science Officer at the Danaher Corporation. Before Danaher, he served as the Head of Global Drug Discovery at AbbVie Inc. Previously, Dr. Gutierrez-Ramos was Group SVP, Biotherapeutics R&D at Pfizer Inc., and SVP and CEDD Head of Immuno Inflammation at GlaxoSmithKline plc. He was the founding CEO and President at Repertoire Immune Medicine, where he built and led a team to decode the human immunome. Previously, Dr. Gutierrez-Ramos was President and CEO of Synlogic, Inc., where he led the company from early discovery to the clinical stage and the public markets. As a biotech leader or in global positions, he oversaw multiple drug discovery teams, resulting in five marketed drugs. He previously served in a series of progressively more responsible research and development roles at Avidia and Millennium Pharmaceuticals, Inc.

Before working in the private sector, Dr. Gutierrez-Ramos was a tenure track professor at Harvard Medical School in the Department of Genetics. He was also a professor for the Spanish Scientific Research Council at the National Center of Biotechnology in Madrid, Spain. He was a scientist and member at the prestigious Basel Institute for Immunology in Basel, Switzerland, and a Postdoctoral Fellow at the Max Plank Institute for Immunbiologie in Freiburg, Germany.

Dr. Gutierrez-Ramos said: “It will be a pleasure working with Bicycle again. Bicycles represent a new modality and a truly unique innovative technology, and I firmly believe in their potential to improve treatment options for patients suffering from a wide range of diseases with insufficient treatment options. I look forward to working with the team once again to advance these promising new medicines to change the treatment paradigm for patients.”

Dr. Gutierrez-Ramos earned a Ph.D. from the Immunology Department of the Center for Molecular Biology at the Universidad Autonoma de Madrid, Spain, and a Bachelor of Science degree, summa cum laude, in Chemistry with a minor in Biochemistry from the Universidad Complutense de Madrid, Spain.

About Bicycle Therapeutics

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small-molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle’s lead product candidate, BT1718, a Bicycle Toxin Conjugate that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial in collaboration with the Centre for Drug Development of Cancer Research UK. Bicycle is also evaluating BT5528, a second-generation BTC targeting EphA2, in a company-sponsored Phase I/II trial. BT8009 is a BTC targeting Nectin-4, a well-validated tumor antigen, and is also currently being evaluated in a Company-sponsored Phase I/II trial. Bicycle is headquartered in Cambridge, UK with many key functions and members of its leadership team located in Lexington, MA.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.